Immunization of large mammals with low doses of RNA
AssigneeGlaxosmithkline Biologicals SA
InventorAndrew Geall
Life of this patent
Estimating the term…
Abstract
RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
Claims30
A method of eliciting an antibody response against a respiratory syncytial virus (RSV) surface fusion glycoprotein (F protein) immunogen by an immune system in a large mammal, the method comprising administering intramuscularly to the large mammal at least two unit doses;
- each unit dose comprising a composition comprising liposomes and messenger ribonucleic acid (mRNA) molecules;
- the mRNA molecules comprising a poly-adenosine monophosphate (poly(A)) tail and a sequence that encodes the RSV F protein immunogen;
- each unit dose comprising between 2 μg and 100 μg of the mRNA molecules;
- the at least two unit doses being sequential and administered at least 1 week apart;
- the administering comprising contacting the composition with skeletal muscle;
- the liposomes comprising a cationic lipid;
- the cationic lipid comprising a tertiary amine;
- the liposomes encapsulating at least half of the mRNA molecules;
- and the large mammal being a human or a cow.
A method of eliciting an antibody response against a RSV F protein immunogen by an immune system in a large mammal, the method comprising administering intramuscularly to the large mammal at least two unit doses, each unit dose comprising a composition comprising liposomes and mRNA molecules;
- the mRNA molecules comprising a poly(A) tail and a sequence that encodes the RSV F protein immunogen;
- each unit dose comprising between 0.5 μg and 1.5 μg of the mRNA molecules per kg of the body mass of the large mammal;
- the at least two unit doses being sequential and administered at least 1 week apart;
- the administering comprising contacting the composition with skeletal muscle;
- the liposomes comprising a cationic lipid;
- the cationic lipid comprising a tertiary amine;
- the liposomes encapsulating at least half of the mRNA molecules;
- and the large mammal being a human or a cow.
Dependencies are inferred from the claim text.